Skip to main content

Peer Review reports

From: Inflammatory markers predict survival in patients with postoperative urothelial carcinoma receiving tislelizumab (PD-1 inhibitor) adjuvant therapy

Original Submission
17 Dec 2023 Submitted Original manuscript
8 Jan 2024 Reviewed Reviewer Report
8 Jan 2024 Reviewed Reviewer Report - Zhuohan Lao
8 Jan 2024 Reviewed Reviewer Report
24 Jan 2024 Author responded Author comments - Haitao Zhu
25 Jan 2024 Author responded Author comments - Haitao Zhu
Resubmission - Version 2
24 Jan 2024 Submitted Manuscript version 2
1 Feb 2024 Reviewed Reviewer Report - Zhuohan Lao
4 Feb 2024 Reviewed Reviewer Report
4 Feb 2024 Reviewed Reviewer Report
Resubmission - Version 3
Submitted Manuscript version 3
Publishing
6 Feb 2024 Editorially accepted
12 Feb 2024 Article published 10.1186/s12885-024-11969-5

You can find further information about peer review here.

Back to article page